B
Bull
Bull · 25%OCS
$18.72
Szenariopreis
$12.180
-0.069 (-0.57%)Zum Schluss
Loading chart…
- High
- 12.235
- Open
- 12.030
- VWAP
- 12.14
- Vol
- 83.36K
- Mkt Cap
- 543.39M
- Low
- 12.010
- Amount
- 1.01M
- EV/EBITDA, TTM
- -2.20
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
AI analysis of Oculis Holding AG (OCS)
holdOculis Holding AG is currently not a strong buy due to its low RSI of 24.749, indicating oversold conditions, and a significant YTD change of -38.95%. While the recent positive FDA feedback on Privosegtor could provide future upside, the company has reported consistent losses, with a net income of -28,852,000 CHF in Q1 2026 and a forward P/E of 0, suggesting uncertainty in profitability. The primary risk is the ongoing negative sentiment reflected in the stock's decline and the downgrades from analysts, with the lowest target at $23, which is significantly below the current price of $12.21.
Bewertungskennzahlen
The current forward P/E ratio for Oculis Holding AG (OCS) is 0.00, compared to its 5-year average forward P/E of -5.72.
Alphio AI Price Scenarios for OCS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding OCS
Event-Zeitleiste
News
9.008-24NewsfilterOculis Initiates PIONEER-1 Trial for Privosegtor in Optic Neuritis
8.508-10GlobenewswireOculis Acquires Privosegtor to Enhance Strategic Flexibility
8.508-10GlobenewswireOculis Enters Asset Purchase Agreement with Accure
- 8.508-10Newsfilter
Oculis Acquires Privosegtor to Enhance Strategic Flexibility
9.508-07NASDAQ.COMOculis Holding AG Reports Better-Than-Expected Quarterly Loss
OCS FAQ — answered by Alphio AI
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide. It operates in the Healthcare sector.
Oculis Holding AG is currently not a strong buy due to its low RSI of 24.749, indicating oversold conditions, and a significant YTD change of -38.95%. While the recent positive FDA feedback on Privosegtor could provide future upside, the company has reported consistent losses, with a net income of -28,852,000 CHF in Q1 2026 and a forward P/E of 0, suggesting uncertainty in profitability. The primary risk is the ongoing negative sentiment reflected in the stock's decline and the downgrades from analysts, with the lowest target at $23, which is significantly below the current price of $12.21.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.